Detail akcie Cybin Rg online

Business Summary: Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N, N-dimethyltryptamine (DMT) and dDMT programs create a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II.CYB005 is in Preclinical stage. It has an intellectual property portfolio in the psychedelic drug development sector with over 80 patents granted and over 230 patent applications pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.
Financial Summary: BRIEF: For the six months ended 30 September 2025, Cybin Inc revenues was not reported. Net loss increased 11% to C$58.3M. Higher net loss reflects Research - Balancing value increase from C$7.4M to C$28.2M (expense), Debt issuance costs increase from C$0K to C$2.9M (expense), Professional and consulting fees increase from C$1.1M to C$3.9M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -C$2.64 to -C$2.49.